This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
GEHC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GEHC vs. BSX: Which Stock Is the Better Value Option?
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
Compared to Estimates, GE HealthCare (GEHC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Technologies (GEHC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of +16.48% and +0.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
by Moumi Mondal
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
by Zacks Equity Research
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
Top Analyst Reports for Cisco, Caterpillar & Charles Schwab
by Mark Vickery
CSCO, CAT and SCHW shares outperformed peers as analysts highlight growth drivers and risks in key business segments.
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Valneva (VALN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum
by Sridatri Sarkar
TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
by Moumi Mondal
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
3 AI-Driven Medical Device Stocks to Watch in 2025
by Sridatri Sarkar
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
SNN vs. GEHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNN vs. GEHC: Which Stock Is the Better Value Option?
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
by Zacks Equity Research
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.
GE HealthCare's Flyrcado Sets New Benchmark in Cardiac PET Imaging
by Zacks Equity Research
GEHC's Flyrcado gains momentum with FDA approval, CMS support, and expanding coverage in cardiac PET imaging.
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
by Indrajit Bandyopadhyay
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
by Zacks Equity Research
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
by Zacks Equity Research
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
by Moumi Mondal
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Why Is Perrigo (PRGO) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
by Zacks Equity Research
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
by Zacks Equity Research
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
by Zacks Equity Research
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
by Zacks Equity Research
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.